Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Kyle LaHucik

Senior Reporter

Ampersand Biomedicines, a biotech working on medicines “similar in principle” to antibody-drug conjugates, has secured $65 million in a Series B round.

Eli Lilly took …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Immunovant will not take rare disease drug to regulators despite Phase 3 win

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Sixteen-year-old dies after receiving Sarepta’s Duchenne gene therapy

Updated: Novartis revamps cardiovascular commercial strategy as Entresto patent cliff looms

Stem cell company bit.bio cuts quarter of staff, drops therapeutics focus

Flag­ship's Am­per­sand gets Eli Lil­ly's sup­port in $65M Se­ries B

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Flagship's Ampersand gets Eli Lilly's support in $65M Series B